NDA 019193 · Methapharm
Provocholine
Methacholine Chloride · Inhalation
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jun 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Oct 31, 1986
Approved uses
2
Original approval plus efficacy supplements
Registered trials
67
12 Phase 3, 2 recruiting
FAERS reports
73
36 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEVERE BRONCHOCONSTRICTION WARNING: SEVERE BRONCHOCONSTRICTION Severe bronchoconstriction can result from Provocholine administration (including the lowest dose). The use of Provocholine is contraindicated in pediatric and adult patients with baseline FEV1 < 60% predicted or adults with FEV1 < 1.5 L. Because of the potential for severe bronchoconstriction, the use of Provocholine in patients with clinically apparent asthma or wheezing is not recommended [ see Warnings and Precautions (5.1) ]. Emergency equipment and medication should be immediately available to treat acute respiratory distress. If severe bronchoconstriction occurs, reverse immediately with a rapid-acting inhaled bronchodilator agent (β-agonist) [ see Warnings and Precautions (5.1) ]. If baseline spirometry is not performed or is measured inaccurately, the initial FEV1 may be underestimated. In this situation,...
What it is approved for
From the label in effect Jul 15, 2026.
Provocholine, used in a methacholine challenge test, is indicated for the diagnosis of bronchial airway hyperreactivity in adults and pediatric patients five years of age and older who do not have clinically apparent asthma. Provocholine, a cholinergic agonist used in a methacholine challenge test, is indicated for the diagnosis of bronchial airway hyperreactivity in adults and pediatric patients five years of age and older who do not have clinically apparent asthma (1)
Mechanism: Methacholine chloride is a cholinergic agonist. Bronchial smooth muscle contains significant parasympathetic (cholinergic) innervation. Methacholine chloride agonizes the muscarinic receptors which eventually induce bronchoconstriction.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 8, 2019 Supplement 21 · Efficacy LabelLetter
- Oct 31, 1986 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- PROVOCHOLINE · METHACHOLINE CHLORIDE 1600MG/VIAL · FOR SOLUTION, INHALATION · Discontinued
- PROVOCHOLINE · METHACHOLINE CHLORIDE 100MG/VIAL · FOR SOLUTION, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Methacholine Chloride" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Sensitivity and Specificity of Inhaled Methacholine in Bronchial Provocation TestStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05634473 · 280 participants (planned) · Start Dec 2022 · Primary completion Feb 2023
Drug: Methacholine Chloride · For: Asthma
Sites: Beijing, China; Lanzhou, China; Guangzhou, China · 12 sites in all
- Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected AsthmaticsPivotal-lookingCompleted
SyntaraIndustry
NCT00252291 · 240 participants · Start Nov 2005
Drug: Aridol; Methacholine · For: Asthma
Sites: Denver, Colorado
- MethaCholine Bronchoprovocation Study (MeCIS)Pivotal-lookingCompleted
Johns Hopkins Bloomberg School of Public HealthAcademic, hospital or other
NCT00705341 · 219 participants · Start Jan 2009 · Primary completion Feb 2010
Drug: fluticasone · For: Asthma
Sites: San Diego, California; Jacksonville, Florida; Miami, Florida · 13 sites in all
- Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild AsthmaPivotal-lookingCompleted
Lupin, Inc.Industry
NCT02584257 · 217 participants · Start Apr 2016 · Primary completion Aug 2016
Drug: placebo ProAir HFA; ProAir HFA and 2 more · For: Mild Persistent Asthma
Sites: Huntington Beach, California; Mission Viejo, California; Rolling Hills Estates, California · 17 sites in all
- Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma MedicationsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00158834 · 200 participants · Start Nov 1999
Drug: Salmeterol/Fluticasone propionate combination product; Fluticasone propionate · For: Asthma
Sites: Alkmaar, Netherlands; Almere Stad, Netherlands; Amsterdam, Netherlands · 16 sites in all
- Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge TestingPivotal-lookingCompleted
Orion Corporation, Orion PharmaIndustry
NCT05084222 · 180 participants · Start Nov 11, 2021 · Primary completion Jun 30, 2023
Drug: Buventol® Easyhaler® 200 µg/inhalation dmDPI; Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI and 1 more · For: Asthma
Sites: Helsinki, Finland; Tampere, Finland
- Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild AsthmaPivotal-lookingRecruiting
Intech Biopharm Ltd.Industry
NCT04912596 · 148 participants (planned) · Start Aug 15, 2022 · Primary completion Jan 31, 2025
Drug: Albuterol Sulfate inhalation aerosol 108 mcg per actuation; Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation · For: Mild Asthma
Sites: Ahmedabad, India; Belagāve, India; Kolkata, India · 12 sites in all
- BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild AsthmaPivotal-lookingCompleted
Cipla Ltd.Industry
NCT06154304 · 120 participants · Start Dec 6, 2023 · Primary completion Sep 16, 2024
Drug: Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation); Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 and 2 more · For: Bronchial Asthma
Sites: Medford, Oregon
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chest discomfort8
- dyspnoea7
- fatigue7
- headache6
- dizziness5
- drug ineffective5
- urticaria5
- angioedema4
- anxiety4
- asthma4
- benign prostatic hyperplasia4
- pain4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 7 |
| 2012 | 3 |
| 2013 | 1 |
| 2015 | 3 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 7 |
| 2020 | 8 |
| 2021 | 3 |
| 2022 | 7 |
| 2023 | 4 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Provocholine (Methacholine Chloride) · HCPCS J7674
2024 spending
$76K
Beneficiaries
1,905
1,914 claims
Per beneficiary
$40
2024 ASP limit $1.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $68,767 |
| 2021 | $82,585 |
| 2022 | $54,574 |
| 2023 | $53,164 |
| 2024 | $75,743 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans.
Beckman JA, Goldfine AB, Gordon MB, et al. · Circulation 2001 · Clinical Trial, Research Support, Non-U.S. Gov't
- Diagnostic comparison of methacholine and mannitol bronchial challenge tests for identifying bronchial hyperresponsiveness in asthma: a systematic review and meta-analysis.
Lee J, Song JU · J Asthma 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Modification of forearm resistance vessels by exercise training in young men.
Green DJ, Cable NT, Fox C, et al. · J Appl Physiol (1985) 1994 · Clinical Trial, Comparative Study
- A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered- dose inhalers.
Creticos PS, Adams WP, Petty BG, et al. · J Allergy Clin Immunol 2002 · Clinical Trial, Randomized Controlled Trial
- Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans.
Beckman JA, Goldfine AB, Gordon MB, et al. · Circ Res 2002 · Clinical Trial, Randomized Controlled Trial
- A clinical and structural comparison of industrial methacholine and provocholine.
Sherman CB, Kern DG, Corwin RW, et al. · Chest 1994 · Clinical Trial, Comparative Study
Sponsor: Methapharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.